Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2764-9. doi: 10.1073/pnas.1415525112. Epub 2015 Feb 9.

Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia.

Author information

1
Department of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan;
2
Laboratory for Malignancy Control Research, Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan; kataoka.naoyuki.6m@kyoto-u.ac.jp hagiwara.masatoshi.8c@kyoto-u.ac.jp.
3
Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Tokyo 113-8510, Japan;
4
Department of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan; Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan;
5
Department of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan; Medical Research Support Center, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan;
6
Laboratory of Chemical Bioscience, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo 101-0062, Japan;
7
Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom;
8
Department of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan; KinoPharma, Inc., Tokyo 154-0024, Japan; and.
9
Laboratory of Gene Expression, School of Biomedical Science, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.
10
Department of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan; kataoka.naoyuki.6m@kyoto-u.ac.jp hagiwara.masatoshi.8c@kyoto-u.ac.jp.

Abstract

Familial dysautonomia (FD), a hereditary sensory and autonomic neuropathy, is caused by missplicing of exon 20, resulting from an intronic mutation in the inhibitor of kappa light polypeptide gene enhancer in B cells, kinase complex-associated protein (IKBKAP) gene encoding IKK complex-associated protein (IKAP)/elongator protein 1 (ELP1). A newly established splicing reporter assay allowed us to visualize pathogenic splicing in cells and to screen small chemicals for the ability to correct the aberrant splicing of IKBKAP. Using this splicing reporter, we screened our chemical libraries and identified a compound, rectifier of aberrant splicing (RECTAS), that rectifies the aberrant IKBKAP splicing in cells from patients with FD. Here, we found that the levels of modified uridine at the wobble position in cytoplasmic tRNAs are reduced in cells from patients with FD and that treatment with RECTAS increases the expression of IKAP and recovers the tRNA modifications. These findings suggest that the missplicing of IKBKAP results in reduced tRNA modifications in patients with FD and that RECTAS is a promising therapeutic drug candidate for FD.

KEYWORDS:

RNA disease; neurodegenerative disease; small molecules; splicing; tRNA modification

PMID:
25675486
PMCID:
PMC4352824
DOI:
10.1073/pnas.1415525112
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center